Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000822
UniProt IDP10515
Primary gene name(s)DLAT
Synonym gene name(s)DLTA
Protein nameDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
Protein functionThe pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2, and thereby links the glycolytic pathway to the tricarboxylic cycle.
Subcellular locationMitochondrion matrix.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P10515
Gene Ontology
(Biological Process)
Complete annatation
acetyl-CoA biosynthetic process from pyruvate [GO:0006086];
glucose metabolic process [GO:0006006];
glyoxylate metabolic process [GO:0046487];
pyruvate metabolic process [GO:0006090];
regulation of acetyl-CoA biosynthetic process from pyruvate [GO:0010510];
sleep [GO:0030431];
tricarboxylic acid cycle [GO:0006099]
Gene Ontology
(Molecular Function)
Complete annatation
dihydrolipoyllysine-residue acetyltransferase activity [GO:0004742]
Gene Ontology
(Cellular Component)
Complete annatation
mitochondrial matrix [GO:0005759];
mitochondrial pyruvate dehydrogenase complex [GO:0005967];
mitochondrion [GO:0005739];
myelin sheath [GO:0043209];
pyruvate dehydrogenase complex [GO:0045254]
Protein-protein interaction108081
Phylogenetic treeP10515
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.254801444734420.0001627860217431330.000740794359816577
AZA vs. DISU0.06421787585618490.8008859368151240.983438610789082
AZA vs. IL70.3621252238208990.06198915891284670.717085642588902
AZA vs. SAHA-0.2755642798761950.2619020561159490.633998971236841
DISU vs. CD3-1.202145717374330.001070938326413810.00439768829698217
DISU vs. IL70.2890433709303150.2530480020920790.639299251137604
DISU vs. SAHA-0.3392442179952560.2467031860770140.624704935827561
DMSO vs. AZA-0.04874862958779230.7737768651255431
DMSO vs. CD3-1.314638608615955.28156001035063e-050.000254531994740666
DMSO vs. DISU-0.1146735955519930.6401683561847880.9472626202031
DMSO vs. IL70.4180298215087380.02125931730613250.298959149617488
DMSO vs. SAHA-0.2339567703965210.3239809741529850.677498689586097
HIV vs. Mock in Activation-0.08657959343887110.8893732532678280.999983755607037
HIV vs. Mock in Latency-0.06222015276111220.7095844457159650.999834320637052
IL7 vs. CD3-0.8841898944137880.006289020274344860.0203334196900901
SAHA vs. CD3-1.555269016621781.68919561589487e-059.92443584075464e-05
SAHA vs. IL7-0.6414067382392080.009004787830558910.0579031834052749
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.423953 0.000580925
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.991 1.01 1.016 1.045 0.919
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00157 NADH nutraceutical unknown unknown
DB03758 Radicicol experimental unknown unknown
DB03760 Dihydrolipoic Acid experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1FYC NMR - A=212-315.
1Y8N X-ray 2.6Å B=212-319.
1Y8O X-ray 2.4Å B=212-319.
1Y8P X-ray 2.6Å B=212-319.
2DNE NMR - A=92-186.
2PNR X-ray 2.5Å C/G=212-319.
2Q8I X-ray 2.6Å B=212-319.
3B8K EM 8.8Å A=409-647.
3CRK X-ray 2.3Å C/D=214-300.
3CRL X-ray 2.6Å C/D=214-300.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00010 Glycolysis / Gluconeogenesis - Homo sapiens (human)
hsa00020 Citrate cycle (TCA cycle) - Homo sapiens (human)
hsa00620 Pyruvate metabolism - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa01200 Carbon metabolism - Homo sapiens (human)